Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Christopher L. Moertel, MD
Advertisement
Christopher L. Moertel, MD, serves as medical director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs and professor of pediatric hematology and oncology at the University of Minnesota.
Articles by Christopher L. Moertel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
5